Gold Coast Health Plan (GCHP) Medi-Cal Clinical Guidelines Hyaluronic Acid Derivatives (Durolane™ Euflexxa ™, Gel-One ™, Gelsyn-3 ™, GenVisc 850 ™, Hyalgan ™, Hymovis ™, Monovisc ™, Orthovisc ™, Supartz-FX ™, Synvisc ™, Synvisc-One ™, Triluron ™, TriVisc ™, Visco-3 ™)

PA Criteria	Criteria Details
Covered Uses (FDA approved indication)	*Durolane, Euflexxa, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz FX, Synvisc, Synvisc-One, Triluron, Trivisc, Visco-3*: Treatment of pain in osteoarthritis of the knee in patients who have failed nonpharmacologic treatment and simple analgesics (e.g. acetaminophen). *Gel-One*: Treatment of pain in osteoarthritis of the knee in patients who have failed nonpharmacologic treatment, nonsteroidal anti-inflammatory drugs (NSAIDs) or simple analgesics, e.g. acetaminophen.
Exclusion Criteria	Treatment for pain in the knee due to causes other than osteoarthritis, such as gout, rheumatoid arthritis. Treatment for pain management for area(s) other than knee. Active joint infection Bleeding disorder
Required Medical Information	Initial Therapy • Documented clinical diagnosis of osteoarthritis of the knee. • At least one (1) course of physical therapy for knee osteoarthritis. • Documented failure, inadequate response, or intolerance to at least two (2) out of the three (3) below (e.g. i and ii; i and iii, or ii and iii): i. 2 oral or topical [e.g., oral non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, or topical NSAIDS (e.g., diclofenac 1 percent gel)], ii. Acetaminophen, iii. 1 or more trial in the last 12 months of intra-articular steroid injections unless intolerant or contraindicated. Continuation • Documentation of positive clinical outcome from previous use of hyaluronic acid derivative At least 6-month interval from prior hyaluronic acid derivative use
Age Restriction	18 years and older except Durolane, Synojoynt and Visco-3, 22 years and older 18 - 21 years of age – check for CCS
Prescriber Restrictions	Rheumatology, Orthopedics, and pain management
Coverage Duration	One treatment series per knee at intervals no more frequent than 6 months
Other Criteria/Information	

HCPCS	Description	Dosing, Units

	J7318	Hyaluronan or derivative, for intra-articular injection, 1mg (Durolane™)	60mg once (60 units per dose)
	J7320	Hyaluronan or derivative, for intra-articular injection, 1mg (GenVisc 850 ™)	25mg once weekly x 5 weeks (25 units per dose)
	J7321	Hyaluronan or derivative, for intra-articular injection, 1mg (Hyalgan ™)	20mg once weekly x 5 weeks (1 unit per dose)
	J7321	Hyaluronan or derivative, for intra-articular injection, 1mg (Supartz FX ™)	25mg once weekly x 5 weeks (1 unit per dose)
	J7322	Hyaluronan or derivative, for intra-articular injection, 1mg (HymovisFX ™)	24mg once weekly x 2 weeks (24 units per dose)
	J7323	Hyaluronan or derivative, for intra-articular injection, 1mg (Euflexxa ™)	20mg once weekly x 3 weeks (1 unit per dose)

	J7325	Hyaluronan or derivative, for intra-articular injection, 1mg (Syynvisc™)	16mg once weekly x 3 weeks (16 units per dose)
	J7325	Hyaluronan or derivative, for intra-articular injection, 1mg (Synvisc-One™)	48mg once (48 units per dose)
	J7326	Hyaluronan or derivative, for intra-articular injection, 1mg (Gel-One™)	30mg once (1 units per dose)
	J7327	Hyaluronan or derivative, for intra-articular injection, 1mg (Monovisc™)	88mg once (1 unit per dose)
	J7328	Hyaluronan or derivative, for intra-articular injection, 1mg (Gelsyn-3™)	16.8mg once weekly x 3 weeks (168 units per dose)
	J7329	Hyaluronan or derivative, for intra-articular injection, 1mg (Trivisc™)	25mg once weekly x 3 weeks (25 units per dose)

	J7331	Hyaluronan or derivative, for intra-articular injection, 1mg (Synojoynt ™)	20mg once weekly x 3 weeks (20 units per dose)
	J7332	Hyaluronan or derivative, for intra-articular injection, 1mg (Triluron ™)	20mg once weekly x 3 weeks (20 units per dose)

STATUS	DATE REVISED	REVIEW DATE	APPROVED/REVIEWED BY	EFFECTIVE DATE
Created	Aug. 5, 2024	Aug. 5, 2024	Yoonhee Kim, Interim Director of Pharmacy Services	N/A
Approved	N/A	Aug. 15, 2024	Pharmacy & Therapeutics (P&T) Committee	March 1, 2025